Based on this principle, PD-1/PD-L1 antibodies were established to constrain the PD-1/PD-L1 signaling pathway by binding to receptors on the surface of T lymphocytes or tumor cells in the late stages of peripheral tissue regulation of T-lymphocyte function, thereby disrupting the immune response, preventing tumor cell immune escape, and ensuring a normal immune response (10). Here, CD274 is linked to neoplasm.